ArticleInternational journal of general medicine2026
Circular RNA Hsa_circ_0062403 Acts as a Potential Prognostic Biomarker for Early Recurrence of Hepatocellular Carcinoma.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Circular RNAs (circRNAs) have been shown to have critical regulatory roles in hepatocellular carcinoma (HCC). This study aims to investigate the predictive value of circLZTR1 for early recurrence of HCC. Patients and Methods: In this study, circLZTR1 (a circRNA derived from the LZTR1, hsa_circ_0062403) was identified and validated in the HCC cohort. Univariate analyses and multivariate Cox regression were conducted to analyze the functional role of hsa_circ_0062403 in the postoperative early recurrence of HCC patients. Receiver operating characteristic curve (ROC) analysis was performed to assess the predictive performance of hsa_circ_0062403 for early recurrence. Results: 91 patients with HCC after surgery were included. circLZTR1 was downregulated in early recurrence HCC patients and predicted poor recurrence-free survival (P=0.029). In addition, a significant downregulation of circLZTR1 was observed in HCC from patients with MVI or PVTT. Multivariate Cox regression analysis indicated that lower circLZTR1 (>0.25 vs <0.1; HR = 0.142, 95% CI: 0.042-0.482, P = 0.002), higher AFP (>400 vs <20; HR = 7.880, 95% CI: 2.499-24.844, P < 0.001), higher INR (HR = 4.203, 95% CI: 1.133-15.588, P = 0.032), multiple tumors (HR = 3.795, 95% CI: 1.541-9.346, P = 0.004), PVTT positive (HR = 3.438, 95% CI: 1.050-11.258, P = 0.041), and larger tumor diameter (HR = 1.306, 95% CI: 1.101-1.550, P = 0.002) served as independent risk factor for early recurrence of HCC. ROC analysis indicated that the Cox model demonstrated higher sensitivity and specificity than the clinical model and single circLZTR1 in prediction for early recurrence of HCC patients (AUC = 0.767, 95% CI: 0.666-0.868, P < 0.001). Conclusion: The downregulation of circLZTR1 is closely associated with the acquisition of invasive phenotypes, vascular invasion, and subsequent early recurrence of HCC patients, suggesting that circLZTR1 may serve as a novel prognostic biomarker for predicting early recurrence in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.